A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
Completed · Phase 1
Conditions studied: Advanced Solid Tumor
In brief
The purpose of this first-in-human, open-label, multicenter, non-randomized study is to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary clinical activity of ES002023 in patients with advanced solid tumors that are relapsed or refractory to standard therapies.
Key facts
- Study ID
- NCT05075564
- Run by
- Elpiscience Biopharma, Ltd.
- People needed
- 8
- Starts
- 2021-12-23
- Expected to finish
- 2022-10-13
- Last updated by the study team
- 2025-05-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- HonorHealth — Scottsdale, Arizona, United States
- Fayetteville Oncology — Fayetteville, Arkansas, United States
- UCLA — Los Angeles, California, United States
- Sarah Cannon Research Institute — Orlando, Florida, United States
- Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
- NEXT Austin — Austin, Texas, United States
- NEXT Virginia — Fairfax, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.